晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02228 晶泰控股

已收盘 09-21 16:08:36

8.495

+0.475

+5.92%

最高8.725	最低8.150	成交量1.92亿
今开8.275	昨收8.020	日振幅7.17%
总市值365.54亿	流通市值365.54亿	总股本43.03亿
成交额16.12亿	换手率4.47%	流通股本43.03亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02228","market":"HK","secType":"STK","nameCN":"晶泰控股","latestPrice":8.495,"timestamp":1789978116004,"preClose":8.02,"halted":0,"volume":192461932,"delay":0,"changeRate":0.05922693266832914,"floatShares":4303000000,"shares":4303000000,"eps":0.03,"marketStatus":"已收盘","change":0.475,"latestTime":"09-21 16:08:36","open":8.275,"high":8.725,"low":8.15,"amount":1612062842,"amplitude":0.071696,"askPrice":8.495,"askSize":245000,"bidPrice":8.485,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.056,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1790040600000},"marketStatusCode":5,"adr":0,"listingDate":1718208000000,"exchange":"SEHK","adjPreClose":8.02,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":3.64098,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"TPX.HK","impliedVol":1.0727,"impliedVolPercentile":0.9333},"requestUrl":"/m/hq/s/02228/tweets","defaultTab":"tweets","newsList":[{"id":"2669139601","title":"港股异动 | 晶泰控股涨超5% 董事会主席计划增持公司股份 与斯坦福大学达成药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139601","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669139601?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:59","pubTimestamp":1789959566,"startTime":"0","endTime":"0","summary":"$晶泰控股$涨超7%，上一交易日股价大涨超16%。值得一提的是，晶泰科技日前宣布，全资子公司LCC Technologies与斯坦福大学达成药物发现合作协议。双方将结合斯坦福大学在疾病生物学研究领域的专业能力，以及LCC的小分子药物发现平台，共同评估新的生物学发现，并探索其进一步开发为小分子治疗药物的潜力。根据协议，LCC将与斯坦福大学研究人员共同推进具有潜力的研究项目，加速相关发现向药物研发阶段推进。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/4caf8931f0a1325304c29622105193aa","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/4caf8931f0a1325304c29622105193aa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498532.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1141","VXUS","BK1617","KCAI","BK4585","02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669113993","title":"港股异动 | 晶泰控股(02228.HK)涨超7% 董事会主席计划增持公司股份 与斯坦福大学达成药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2669113993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669113993?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:15","pubTimestamp":1789956930,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103699705","title":"异动解读｜晶泰控股盘中上涨5.24%，董事会主席拟斥资不超3200万港元增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1103699705","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103699705?lang=zh_cn&edition=full","pubTime":"2026-09-21 10:06","pubTimestamp":1789956399,"startTime":"0","endTime":"0","summary":"9月21日，晶泰控股盘中上涨5.24%，报8.44港元，成交额7.31亿港元。消息面上，公司当日公告，董事会主席、执行董事兼联合创始人温书豪博士拟于10月末之前以自有资金通过公开市场增持公司股份，增持总代价不超过3200万港元，公司不参与也不会提供任何财务资助。董事会表示，该计划反映温书豪博士对公司长期发展前景及投资价值的信心。此外，公司近期持续在二级市场进行股份回购，9月以来已多次回购并注销股份；附属公司此前亦与斯坦福大学达成AI驱动药物发现合作，多重利好叠加提振市场情绪。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"主席拟斥资增持，晶泰控股盘中拉升","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669418048","title":"晶泰控股(02228)：董事会主席温书豪计划增持公司股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2669418048","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669418048?lang=zh_cn&edition=full","pubTime":"2026-09-21 06:26","pubTimestamp":1789943161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股(02228)发布公告，公司董事会获悉，公司董事会主席、执行董事兼联合创始人温书豪博士基于对集团未来发展前景的信心及对公司长期投资价值的认同，拟于2026年10月末之前，以自有资金于公开市场增持公司的普通股股份。该等增持行为须遵从香港联合交易所有限公司证券上市规则、其他适用法律、法规、相关守则及公司内部控制及证券交易政策。根据增持股份计划，温书豪博士拟合共增持股份的总代价不超过港币3200万元。每次股份购买将按当时市场价格进行。公司将不会参与或为增持股份计划提供任何财务资助。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1498423.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175805711","title":"晶泰控股（02228）披露董事会主席计划于2026年前斥资不超3,200万港元增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1175805711","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175805711?lang=zh_cn&edition=full","pubTime":"2026-09-21 06:16","pubTimestamp":1789942592,"startTime":"0","endTime":"0","summary":"晶泰控股有限公司于2026年9月21日发布自愿性公告称，公司董事会主席、执行董事兼联合创始人温书豪博士计划在2026年10月末之前，以个人自有资金通过公开市场累计增持公司普通股，增持总代价不超过3,200万港元。晶泰控股不参与本次增持，也不会为该计划提供任何财务资助。董事会表示，增持计划反映温书豪博士对公司长期发展前景及投资价值的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144605588","title":"港股异动丨政策利好+顶级学术合作，晶泰控股放量大涨超13%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144605588","media":"格隆汇","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144605588?lang=zh_cn&edition=full","pubTime":"2026-09-18 13:33","pubTimestamp":1789709613,"startTime":"0","endTime":"0","summary":"晶泰控股今日放量拉升，盘中涨超13%，截至目前成交6.89亿港元。个股消息面上，晶泰控股公布，其全资附属LCC Technologies Ltd.，与斯坦福大学校董会已订立一项药物发现合作协议。合作结合斯坦福大学的疾病生物学研究与LCC Technologies的自动化及AI驱动小分子药物发现平台，以加快并推动新药的开发。根据合作，斯坦福大学的主要研究员将有机会根据其研究向斯坦福大学与LCC Technologies成立的联合指导委员会提出项目。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/2deff7f9f3cc3905bf816d65fae9aca2","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/2deff7f9f3cc3905bf816d65fae9aca2"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/news/5314270","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"政策利好+顶级学术合作，晶泰控股放量大涨","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_fund_highlight","symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2668191239","title":"港股午评|恒生指数早盘涨0.67%     AI制药板块大涨","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191239","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191239?lang=zh_cn&edition=full","pubTime":"2026-09-18 12:00","pubTimestamp":1789704004,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，港股恒生指数涨0.67%，涨164点，报24768点；恒生科技指数涨1.74%。港股早盘成交1070亿港元。十部门印发医药十五五规划，机构看好医药迎“Claude”时刻。AI制药进入战略入局阶段。曦智科技-P涨超17%。天数智芯涨超13%，公司有望持续受益AI资本开支的增长及算力自主可控浪潮。MINIMAX-W涨13%，旗下多款产品通过Singtel AI Pass纳入配套订阅计划。俊知集团涨超10%，收购青海中利光纤技术有望打开AI算力相关光纤产品增量空间。大股东解禁期满。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497792.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0561508036.HKD","IE0032431581.USD","03417","00992","01818","LU0572940350.SGD","07300","BK1576","IE0034224299.USD","LU1188198961.HKD","300077","LU0862451753.SGD","02701","LU0128522157.USD","BK1197","HSI","01300","TCHI","LU0320764755.SGD","BK1161","LU0417516902.SGD","BK1617","LU0181495838.USD","02670","BK1117","03115","LU0828237940.HKD","07630","BK1592","BK1526","BK1163","BK1544","LU0672654166.SGD","07552","02656","LU1366334578.USD","03033","HK0000306701.USD","00100","09067","BK1183","603127","BK1574","82800","BK1193","02142","03032","LU0572939691.SGD","LU0890818403.SGD","07666","LU0972618739.USD","600547","03423","LU0543330483.HKD","LU1785774172.SGD","LU0244354667.USD","LU0048580855.USD","LU0310800965.SGD","02833","LNVGY","07200","LU0029875118.USD","BK1237","LU0791590937.USD","02228","LU1808992512.USD","LU0791591158.USD","MCHmain","BK1607","01879","LU0862451837.USD","BK1506","03067","LU0370786039.SGD","LU0049112450.USD","HK0000320264.USD","BK1141","03088","02837","LU1267930227.SGD","03696","LU0128525689.USD","06127","BK1583","LU0326950275.SGD","02800","06658","LU0463099449.HKD","HK0000306685.HKD","513600","LU0348827113.USD","IE0003895053.USD","09903","LU2242644610.SGD","LU0052756011.USD","HSTECH","80992","07500","LU0140636845.USD","09088","LU0264606111.USD","HHImain","LU0348825331.USD","BK1149","03037","LU1235295612.USD","09115","07226","83115","LU1366334651.USD","LU1831875114.USD","IE00B0JY6N72.USD","03419","HK0000320223.HKD","BK1198","LU1046422090.SGD","01787"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668147669","title":"港股异动丨政策利好+顶级学术合作，晶泰控股放量大涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668147669","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668147669?lang=zh_cn&edition=full","pubTime":"2026-09-18 11:53","pubTimestamp":1789703638,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668191646","title":"AI应用板块走高 晶泰控股（02228）涨8.19%、MINIMAX-W（00100）涨5.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2668191646","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668191646?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:40","pubTimestamp":1789695640,"startTime":"0","endTime":"0","summary":"政策配套技改支持、算力券、财政资金和场景对接等措施，有望降低AI转型成本、扩大需求，推动AI应用从局部探索走向系统性落地。我们认为，深入客户核心业务、将行业经验转化为可靠智能体能力、强交付能力的软件厂商，有望受益于存量产品升级与新增智能服务需求，AI应用有望从技术投入转化为企业收入增长与盈利改善。","market":"other","thumbnail":"https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2E2NzVmYjg0MWU1MjU0NDY3MDY2MjI=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991928","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228","BK1141","BK1617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133108308","title":"异动解读｜晶泰控股盘中上涨7.03%，附属公司与斯坦福大学达成AI药物发现合作","url":"https://stock-news.laohu8.com/highlight/detail?id=1133108308","media":"行情直击","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133108308?lang=zh_cn&edition=full","pubTime":"2026-09-18 09:36","pubTimestamp":1789695399,"startTime":"0","endTime":"0","summary":"9月18日，晶泰控股盘中上涨7.03%，报7.405港元，成交额1.08亿港元。消息面上，公司9月17日晚间公告，全资附属公司LCC Technologies Ltd.与斯坦福大学校董会签署药物发现合作协议。根据协议，斯坦福大学在疾病生物学研究中的新生物学见解将接入LCC Technologies的专有PACE小分子药物发现平台，双方成立联合指导委员会推进项目评估与转化。公司表示，此次合作有助于巩固集团在AI+自动化驱动药物发现领域的布局，并为参与早期项目奠定基础。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"晶泰控股异动拉升，携手斯坦福共研AI药物发现","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119490808","title":"晶泰控股附属公司携手斯坦福大学推进AI驱动小分子药物发现","url":"https://stock-news.laohu8.com/highlight/detail?id=1119490808","media":"公告速递","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119490808?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:51","pubTimestamp":1789656680,"startTime":"0","endTime":"0","summary":"2026年9月17日，晶泰控股有限公司发布自愿性公告称，其全资附属公司LCC Technologies Ltd.已与斯坦福大学校董会签署药物发现合作协议。根据协议，斯坦福大学在疾病生物学研究中获得的新生物学见解将接入LCC Technologies的专有PACE小分子药物发现平台，以评估转化为治疗性化合物的可行性。\\n\\n晶泰控股指出，此次合作有助于巩固集团在AI+自动化驱动药物发现领域的布局，并为参与早期项目奠定基础。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668240993","title":"晶泰控股(02228.HK)附属LCC TECHNOLOGIES与斯坦福大学订立药物发现合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2668240993","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668240993?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:49","pubTimestamp":1789656546,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668225993","title":"晶泰控股(02228)附属LCC TECHNOLOGIES与斯坦福大学订立药物发现合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2668225993","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2668225993?lang=zh_cn&edition=full","pubTime":"2026-09-17 22:49","pubTimestamp":1789656546,"startTime":"0","endTime":"0","summary":"智通财经APP讯，晶泰控股 发布公告，公司的全资附属公司LCC Technologies Ltd. 与斯坦福大学校董会已订立一项药物发现合作协议。合作结合斯坦福大学的疾病生物学研究与LCC Technologies的自动化及AI驱动小分子药物发现平台，以加快并推动新药的开发。根据合作，斯坦福大学的主要研究员将有机会根据其研究向斯坦福大学与LCC Technologies成立的联合指导委员会提出项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1497673.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667637517","title":"从万亿算力到“新一代药王”：英伟达AI4S朋友圈的价值分化与产能兑现","url":"https://stock-news.laohu8.com/highlight/detail?id=2667637517","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667637517?lang=zh_cn&edition=full","pubTime":"2026-09-14 12:42","pubTimestamp":1789360925,"startTime":"0","endTime":"0","summary":"随着英伟达与礼来达成最高10亿美元的AI联合实验室合作，顶层资本的共识已经确立。在药物研发中，一次化学幻觉的代价是数月时间和百万美金。目前晶泰已锁定总计7000万美元前置付款，首个肿瘤项目挺进IND-enabling阶段。AI无法彻底抹平临床风险，但能将成药性评价前置，让明显错误的分子尽早出局。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495516.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["FAI","IETC","FTEC","ESUM","NVD","AIPI","USD","USXF","07388","IXN","NULC","ROM","3NVD.UK","ARTY","NVDQ","CHAT","NVII","TYLG","CLSE","METV","NVIW.SI","WISE","ESLG","09788","ANV","NVDA","SMHX","TRFK","AIFD","07788","09388","ILDR","NVDB","ABFL","NVDU","THMR","TTEQ","VGT","2NVD.UK","AGOX","XLK","SNVDAmain","NVDX","SNPE","TTXU","02228","GAMR","LFGY","FDTX","NVDS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167976192","title":"晶泰控股9月11日回购981,000股股份，耗资约675.74万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1167976192","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1167976192?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:32","pubTimestamp":1789129965,"startTime":"0","endTime":"0","summary":"2026年9月11日，晶泰控股有限公司公告称，公司于当日在香港联交所场内回购普通股981,000股，约占其已发行股本的0.0228%。每股回购价格介乎每股6.88港元至6.90港元，累计支付总金额约675.74万港元。此次回购股份计划作注销处理，截至本次公告日尚未进行注销。公告显示，公司于2026年9月7日至9月11日的已发行股本为4,302,716,179股，另有299,000股为库藏股，合计4,303,015,179股。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"晶泰控股9月11日回购981,000股股份，耗资约675.74万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666524111","title":"晶泰控股(02228)9月11日斥资675.74万港元回购98.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666524111","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666524111?lang=zh_cn&edition=full","pubTime":"2026-09-11 20:26","pubTimestamp":1789129577,"startTime":"0","endTime":"0","summary":"晶泰控股(02228)发布公告，于2026年9月11日斥资675.74万港元回购98.1万股。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/gonggaonew/ganggugongg40.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggaonew/ganggugongg40.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1495214.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1617","02228","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161149702","title":"异动解读｜晶泰控股盘中下跌5.14%，中期业绩由盈转亏持续承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1161149702","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1161149702?lang=zh_cn&edition=full","pubTime":"2026-09-11 10:15","pubTimestamp":1789092942,"startTime":"0","endTime":"0","summary":"9月11日，晶泰控股盘中下跌5.14%，报6.835港元，成交额1.47亿港元。消息面上，公司于9月9日发布中期报告，上半年实现营收3.94亿元人民币，同比下降23.9%；录得净亏损2.25亿元，去年同期为净利润7560万元，业绩由盈转亏。收入下滑主要因去年同期确认一笔5100万美元管线授权首付款形成高基数，药物发现解决方案收入同比骤降54%。经调整净亏损为1.06亿元。同行业个股中，英矽智能同日跌5.75%，板块整体承压。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"晶泰控股盘中下跌，中期业绩由盈转亏","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185326117","title":"晶泰控股2026年中期营收3.94亿元，经调整净利润-1.06亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185326117","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185326117?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:33","pubTimestamp":1788960803,"startTime":"0","endTime":"0","summary":"根据公司发布的2026年中期报告显示，晶泰控股在报告期内实现营收3.94亿元，较去年同期的5.17亿元同比下降23.9%。该变化主要由于2025年同期曾确认一笔规模较大的管线授权收入，导致基数较高。经营活动所用净现金流约为3.99亿元，较去年同期的2.38亿元净流出进一步扩大。药物发现解决方案部分实现收入约2.00亿元，较上年同期的4.35亿元下降54.0%，主要原因是对上一报告期内一次性项目收入的高基数影响。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"晶泰控股2026年中期营收3.94亿元，经调整净利润-1.06亿元","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02228"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666536640","title":"晶泰控股：上半财年净亏损2.25亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666536640","media":"南方财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666536640?lang=zh_cn&edition=full","pubTime":"2026-09-09 21:31","pubTimestamp":1788960660,"startTime":"0","endTime":"0","summary":"南财智讯9月9日电，晶泰控股（02228.HK）公告，截至2026年6月30日止六个月，集团净亏损人民币224.9百万元，即2.25亿元；去年同期净利润人民币75.6百万元。营业收入为人民币393.6百万元，即3.94亿元，去年同期为人民币517.1百万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609093869565891.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609093869565891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02228","BK1617","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148739690","title":"港股AI医疗概念股表现活跃，剂泰科技-P涨超9%，英矽智能涨超7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148739690","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148739690?lang=zh_cn&edition=full","pubTime":"2026-09-08 10:17","pubTimestamp":1788833835,"startTime":"0","endTime":"0","summary":"9月8日，港股AI医疗概念股表现活跃，$剂泰科技-P(07666)$涨超9%，$英矽智能(03696)$涨超7%，$金斯瑞生物科技(01548)$涨超6%，$云知声(09678)$涨超4%，$医渡科技(02158)$、$晶泰控股(02228)$涨超2%。","market":"hk","thumbnail":"https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/a5d11890cd6ccd454a56d86737fd3353"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03696","BK4588","ARTY","HK0000306685.HKD","07666","QTOC","5RE.SI","09678","AGIX","BK1617","BK1518","BK1583","01548","CHAT","BK1189","02158","HK0000320223.HKD","BK4585","AIPO","HK0000306701.USD","HK0000320264.USD","BK1109","KCAI","BK1161","BK1141","VXUS","159891","02228","VTHR","BK1576"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"https://www.xtalpi.com","stockEarnings":[{"period":"1week","weight":0.1573},{"period":"1month","weight":0.1093},{"period":"3month","weight":0.2133},{"period":"6month","weight":-0.1558},{"period":"1year","weight":-0.2448},{"period":"ytd","weight":-0.1522}],"compareEarnings":[{"period":"1week","weight":-0.0022},{"period":"1month","weight":-0.0292},{"period":"3month","weight":0.0345},{"period":"6month","weight":-0.0208},{"period":"1year","weight":-0.0676},{"period":"ytd","weight":-0.0343}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"晶泰控股有限公司是一家主要从事为制药及材料科学等产业提供药物及材料科学研发解决方案及服务的控股公司。该公司主要经营两个业务。药物发现解决方案业务从事就新型药物发现工作为各类生物技术与制药公司和学术机构提供模块独立解决方案或与之合作。智能自动化解决方案业务从事提供固态研发服务及自动化化学合成服务。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.06643},{"month":2,"riseRate":0.285714,"avgChangeRate":0.016028},{"month":3,"riseRate":0,"avgChangeRate":-0.069153},{"month":4,"riseRate":0.666667,"avgChangeRate":0.048494},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.010585},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.023767},{"month":7,"riseRate":0.428571,"avgChangeRate":0.047576},{"month":8,"riseRate":0.5,"avgChangeRate":-0.032189},{"month":9,"riseRate":0.8,"avgChangeRate":0.065839},{"month":10,"riseRate":0.6,"avgChangeRate":0.092453},{"month":11,"riseRate":0.5,"avgChangeRate":0.05299},{"month":12,"riseRate":0.5,"avgChangeRate":-0.011625}],"exchange":"SEHK","name":"晶泰控股","nameEN":"XTALPI"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"晶泰控股,02228,晶泰控股股票,晶泰控股股票老虎,晶泰控股股票老虎国际,晶泰控股行情,晶泰控股股票行情,晶泰控股股价,晶泰控股股市,晶泰控股股票价格,晶泰控股股票交易,晶泰控股股票购买,晶泰控股股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"晶泰控股(02228)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供晶泰控股(02228)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}